Yale   

Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy? Are the results of the recently published negative phase II...

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

Is there an advantage to early diagnosis and intervention versus observation until the nodules are amenable to percutaneous biopsy?

Should staging and treatment decisions be made based on imaging alone?

If so, how long is too long to wait?

How, if any, do you utilize genomic testing to guide systemic therapy?

If so, what is your approach to sequencing and timing of targeted therapy and local therapy?

If so do you favor repeat tumor biopsy or cfDNA?

What if the patient has thymoma-associated myasthenia gravis?

When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?

These patients have been largely excluded from these trials.  What if the infection is well controlled?

Would you offer adjuvant TKI following ADAURA data?  Or proceed with durvalumab based on PACIFIC data?

Should fractionated EBRT be administered or can repeat SBRT be used?